← Back to dossier
Patient handout

Acute variceal hemorrhage (esophageal / gastric / ectopic)

PRODUCTION

1. Your condition

This handout is for acute variceal hemorrhage (esophageal / gastric / ectopic). Your care team identified this based on: hematemesis (red or coffee-ground) (baveno vii de franchis 2022).

Other reasons your team may use this plan: melena or hematochezia in cirrhotic patient (baveno vii 2022; aasld 2023); syncope or hypotension in cirrhotic patient (baveno vii 2022 acute bleed criteria); cirrhosis with known varices presenting with bleeding (baveno vii 2022; aasld 2023).

2. Your medications

Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.

MedicationStarting doseHowWhenWhat it does
octreotide50 mcg IV bolus then 50 mcg/h infusionIVcontinuous × 3–5 dReduces splanchnic flow; bridge to EGD (Baveno VII 2022 de Franchis PMID 35120736; AASLD 2023)
ceftriaxone1 g IVIVdaily × 5–7 dReduces SBP and infection mortality (Cochrane; Baveno VII 2022; AASLD 2023; EASL 2018)
terlipressin2 mg IV q4h × 24 h then 1 mg IV q4hIVq4hWhere available; CONFIRM trial benefit in HRS-AKI; ischemic risk (Baveno VII 2022; EASL 2018)
pantoprazole80 mg IV bolus then 8 mg/hIVcontinuous × 72 h then POAcid suppression for PUD if mixed source (ACG 2021 UGIB)
lactulose30–45 mLPO/PRq6h titrateHE risk after blood meal (AASLD 2023 HE guideline; EASL 2018)
rifaximin550 mgPOBIDAdjunct to lactulose for HE prevention (Bass NEJM 2010; AASLD 2023)

Plan: Acute variceal hemorrhage bundle

4. When to seek emergency care

Call 911 or go to the nearest emergency room right away if you have:

  • Hematemesis with hypotension or hemoglobin drop ≥2 g/dL(life-threatening)
  • Child-Pugh B with active bleed at EGD or Child-Pugh C ≤14 within 72 h of EGD
  • Continued bleeding despite band ligation / glue(life-threatening)
  • Ascites + fever / abd pain / leukocytosis in cirrhotic with bleed
  • Variceal bleed in patient on AC / antiplatelet
  • Bleeding gastric varices identified on EGD
  • New AMS / asterixis post bleed

5. Follow-up

Hepatology q1-3 mo; serial EVL until obliteration; transplant evaluation; HE management (Baveno VII 2022 secondary prophylaxis; AASLD 2023)

6. Sources

Guideline: Baveno VII consensus (J Hepatol 2022); AASLD 2017 portal HTN; Garcia-Pagan NEJM 2010 (early TIPS); Villanueva NEJM 2013 (restrictive transfusion)

  1. pubmed.ncbi.nlm.nih.gov/35120736
  2. pubmed.ncbi.nlm.nih.gov/20573925
  3. pubmed.ncbi.nlm.nih.gov/23281973